PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis
Han Li,Ke Su,Lu Guo,Yi Jiang,Ke Xu,Tao Gu,Jiali Chen,Zhenying Wu,Pan Wang,Xi Zhang,Yushan Yan,Siyuan Li,Xue Wu,Lei Han,Kun He,Lianbin Wen,Bo Li,Yunwei Han
DOI: https://doi.org/10.2147/JHC.S415843
2023-07-30
Journal of Hepatocellular Carcinoma
Abstract:Han Li, 1, &ast Ke Su, 1, &ast Lu Guo, 2, &ast Yi Jiang, 1 Ke Xu, 1 Tao Gu, 1 Jiali Chen, 1 Zhenying Wu, 1 Pan Wang, 3 Xi Zhang, 4 Yushan Yan, 1 Siyuan Li, 1 Xue Wu, 1 Lei Han, 5 Kun He, 6 Lianbin Wen, 7 Bo Li, 4 Yunwei Han 1 1 Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 2 Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 3 Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 4 Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 5 Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, 272000, People's Republic of China; 6 Clinical Medical College, Southwest Medical University, Luzhou, 646000, People's Republic of China; 7 Sichuan Provincial People's Hospital, Chengdu, 610072, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yunwei Han; Bo Li, The Affiliated Hospital of Southwest Medical University, 25 TAIPING Street, Luzhou City, Sichuan Province, People's Republic of China, Tel +86-830-3165598 ; +86-830-3165613, Email ; Background: At present, it is not known whether targeting plus immunotherapy combined with transarterial chemoembolization (TACE) can improve the efficacy of hepatocellular carcinoma (HCC). The aim of this retrospective experiment was to explore the difference in clinical efficacy between antiangiogenic drugs plus PD-1 inhibitors combined with and without TACE. Methods: Clinical data of 145 patients with HCC who received anti-angiogenesis therapy plus PD-1 inhibitor combined with TACE (TACE-P-T) (n = 62) or anti-angiogenesis therapy combined with PD-1 inhibitor (P-T) (n = 83) in China from October 2018 to December 2022 were collected and reviewed. We used propensity matching (PSM) to create two groups with comparable baseline scores, compared their median survival time (mOS) and median progression-free survival time (mPFS), and performed subgroup analysis. Results: Before PSM, the mOS and mPFS of patients were 20.3 and 5.0 months in the triple therapy group and 13.6 and 7.4 months in the control group, respectively. After PSM, the mOS and mPFS of patients were 19.7 and 6.6 months in the triple treatment group and 10.5 and 3.7 months in the control group, respectively. Therefore, the TACE-P-T group showed better survival outcomes than P-T. In the subgroup analysis, compared with the control group, the mOS was 10.7 vs 20.3 months in the alpha fetoprotein (AFP) (≥ 400ng/mL/< 400ng/mL) group, 29.3 vs 7.4 months in the alkaline phosphatase (ALP) (≥ 125u/L/< 125u/L) group and 10.5 vs 20.0 months in the Portal vein invasion (PVTT) group. Conclusion: Antiangiogenic therapy combined with PD-1 inhibitors combined with TACE has significant survival benefits for HCC patients. Keywords: HCC, PD-1 inhibitors, antiangiogenic therapy, TACE The incidence of liver cancer has been increasing in many countries in recent decades. As the most common histological type of liver cancer, hepatocellular carcinoma (HCC) accounts for most liver cancer diagnoses and deaths. 1 Chronic viral hepatitis and progressive liver cirrhosis are the main causes of HCC. 2 Based on Barcelona staging (BCLC), the most suitable candidate for TACE is with intermediate-stage HCC (BCLC-B). Patients with stage BCLC-C have found survival benefits in a large number of studies, including a large longitudinal cohort study of 18,031 patients from 14 countries and regions, documenting the experience of patients with HCC in the real world and finding that TACE is the first-line treatment for patients with HCC near stage BCLC-C. 3 So far, the only trial that has reached the main end point for the treatment of advanced HCC between 2003 and 2020 is the TACTICS trial, 4 which compared the efficacy of TACE plus sorafenib with TACE alone. The median mPFS of TACE plus sorafenib was 25.2 months and TACE alone was 13.5 months (HR0.59). At the same time, targeted drugs, mainly including sorafenib and lenvatinib, have been approved as first-line therapies for HCC. In 2020, the combination of atirizumab and bevacizumab showed a better survival rate than sorafenib, the median OS (MOS) is prolonged to 19.2 months, and the o -Abstract Truncated-
oncology